长效干扰素联合利巴韦林对肝移植受者丙型肝炎复发的早期疗效分析  

Early efficacy analysis of peg-interferon plus ribavirin treatment for hepatitis C recurrence after liver transplantation

作　　者：范铁艳[1] 陈虹[1] 沈中阳[1] 田彦[1] 王旭[1] 李俊[1] 

机构地区：[1]武警总医院器官移植研究所,北京100039

出　　处：《中华器官移植杂志》2013年第12期720-722,共3页Chinese Journal of Organ Transplantation

摘　　要：目的探讨肝移植后丙型肝炎复发的受者接受长效干扰素联合利巴韦林治疗的早期疗效。方法总结2002年6月至2012年3月间在单中心接受肝移植且术后丙型肝炎复发受者16例的临床资料，术后应用小剂量聚乙二醇干扰素α-2a＋利巴韦林抗丙型肝炎病毒（HCV）治疗。结果16例中，12例治疗12周内HCVRNA转为阴性，2例HCVRNA水平下降2log，早期应答率达87．5％（14／16）；24周后全部患者HCVRNA转为阴性，转阴性率达100％（16／16）。结论肝移植后丙型肝炎复发可采用长效干扰素联合利巴韦林治疗，其早期应答率较高。Objective hepatitis C recurrence after To study the efficacy of peg liver transplantation. Methods interferon plus ribavirin treatment for The clinical data of 16 patients with hepatitis C recurrence after liver transplantation were collected from June 2002 to March 2012 in our hospital. Results There were 1620 patients receiving liver transplantation. 66 of these patients received the treatment because of hepatitis C related diseases. 16 of the 66 patients received peg- interferon plus ribavirin treatment after liver transplantation. The hepatitis C virus （HCV） RNA concentrations of all the 16 patients were detected. Twelve of the 16 patients were negative for HCV RNA, and the HCV RNA concentration was reduced by more than 2 log after treatment for 12 weeks in 2 cases. The early viral response （EVR） was 87. 5G. The HCV RNA of all the 16 patients became negative after treatment for 24 weeks. Conclusion The EVR was high （87.5%） among patients who received peg-interferon plus ribavirin treatment after liver transplantation, and the combination therapy with interferon plus ribavirin was safe and effective for hepatitis C recurrence after liver transplantation.

关 键 词：肝移植 肝炎 丙型 复发 干扰素Α-2A 利巴韦林 

分 类 号：R657.3[医药卫生—外科学] R512.63[医药卫生—临床医学]